Cardiac Devices InfectionPhase 4RAIDNCT06203769
Reduction of Antibiotherapy Duration for Infections on Implantable Extra Cardiac Devices Leads
A Phase 4 study testing 14-day antibiotic therapy and 28-day antibiotic therapy in people with Cardiac Devices Infection, run by Assistance Publique - Hôpitaux de Paris.
Trial summary
The design is an Open-label randomized controlled multicenter non-inferiority trial with blinded assessor which compares 2 antibiotic strategy: 14-day antibiotic therapy after removal of infected material (experimental group) versus 28-day antibiotic therapy after removal of infected material (control group). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Cardiac Devices Infection
- What is being tested?
- 14-day antibiotic therapy and 28-day antibiotic therapy
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 500 participants
- Where
- No sites listed yet
- Study dates
- 30 Jun 2024to 30 Jun 2028
- Phase
- Phase 4
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age ≥18 years
- Diagnosis of CIED leads infections, defined by:
- Symptoms/signs of systemic infection AND positive blood cultures fulfilled the major Duke microbiological criteria AND echocardiography consistent with vegetation(s) attached to lead(s) AND/OR [18F]FDG PET/CT or radiolabelled WBC SPECT/CT detection of abnormal activity along leads OR
- Symptoms/signs of systemic infection AND NO, signs of generator pocket infection, AND culture, histology or molecular evidence of infection on explanted lead.
- Complete removal of the infected CIED
- Signed informed consent
- French National Health Assurance
Who cannot join
- Current involvement of native or prosthetic heart valve
- Distant infectious foci (such as haematogenous vertebral osteomyelitis, pulmonary abscess…) justifying a prolonged duration of therapy.
- Positive blood culture > 24 hours after cultures despite CIED removal
- CIED infection with Mycobacteria or Fungi
- Women who are pregnant or nursing
- Females of childbearing potential without effective method of birth control
- Patients who are under tutorship or curatorship
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Reduction of Antibiotherapy Duration for Infections on Implantable Extra Cardiac Devices Leads: a Randomized Controlled Multicenter Non-inferiority Trial
The design is an Open-label randomized controlled multicenter non-inferiority trial with blinded assessor which compares 2 antibiotic strategy: 14-day antibiotic therapy after removal of infected material (experimental group) versus 28-day antibiotic therapy after removal of infected material (control group).
Randomization will be centralized, individual 1:1, stratified on center and age (<75 versus >=75 years). Analysis will be reported following CONSORT guidelines for pharmacological trials.
Main analysis will be conducted according to per protocol and intent-to-treat principles. Subgroup analysis will be conducted according to age, classes of antibiotics at baseline and according to resistance testing and baseline renal clearance.
Read the detailed description
Infections of cardiac implantable electronic devices (CIED) are one of the most frequent complication after implantation of these devices, with an incidence rate estimated at 4.82 / 1000 in Denmark, mainly in the first year post implantation. An american study found that the incidence of CIED infection in the USA increased from 1.53% in 2004 to 2.41% in 2008 and a National Inpatient Sample database study showed an increase from 1.45% to 3.41% (P<0.001) from 2000 through 2012. These figures are constantly increasing and concern mostly older people.
Although the mortality seems to be low compared to those of valvular infection , evaluated at 4% for nonstaphylococcal infection and up to 9% for Staphylococcus aureus related infections, those infections are responsible of numerous morbidities such as iterative hospitalizations, decompensations of other comorbidities and autonomy loss, especially, for older people
Clinical presentations of CIED infections are varied and include generator pocket infections, native or prosthetic CIED-associated valvular endocarditis (CIED-IE) with echocardiographic evidence of valve involvement, and CIED lead infections (CIED-LI) with evidence of lead infection without valve involvement.
In CIED infections, removal of the device is the cornerstone of treatment and is usually required to enable cure in association with antimicrobial therapy for a few weeks. However, although antimicrobial therapy duration after removal of the device are relatively well defined for generator pocket infections (10 - 14 days for the remaining skin and soft tissue infection) and CIED-IE (4 - 6 weeks), the optimal duration of antibiotic treatment in CIED-LI has yet to be determined.
Several series amalgamate generator pocket infection, CIED-IE and CIED-LI descript duration of therapy and are therefore unhelpful in deciding on the optimum duration of antimicrobials.
Guidelines for management of CIED infections recommend different durations of antibiotic treatment, particularly for CIED-LI, which can result in considerable inappropriate antimicrobial exposure in a vulnerable patient population.
In light of the emergence of bacterial resistance and in order to limit the drug toxicities of antibiotics, it is crucial to offer patients the shortest possible duration of treatment, without losing efficiency.
Infections of cardiac implantable electronic devices (CIED) are one of the most frequent complication after implantation of these devices, with an incidence rate estimated at 4.82 / 1000 in Denmark, mainly in the first year post implantation(1). An american study found that the incidence of CIED infection in the USA increased from 1.53% in 2004 to 2.41% in 2008 and a National Inpatient Sample database study showed an increase from 1.45% to 3.41% (P<0.001) from 2000 through 2012. These figures are constantly increasing and concern mostly older people.
Although the mortality seems to be low compared to those of valvular infection , evaluated at 4% for nonstaphylococcal infection and up to 9% for Staphylococcus aureus related infections (4), those infections are responsible of numerous morbidities such as iterative hospitalizations, decompensations of other comorbidities and autonomy loss, especially, for older people
Clinical presentations of CIED infections are varied and include generator pocket infections, native or prosthetic CIED-associated valvular endocarditis (CIED-IE) with echocardiographic evidence of valve involvement, and CIED lead infections (CIED-LI) with evidence of lead infection without valve involvement.
In CIED infections, removal of the device is the cornerstone of treatment and is usually required to enable cure in association with antimicrobial therapy for a few weeks. However, although antimicrobial therapy duration after removal of the device are relatively well defined for generator pocket infections (10 - 14 days for the remaining skin and soft tissue infection) and CIED-IE (4 - 6 weeks) (5), the optimal duration of antibiotic treatment in CIED-LI has yet to be determined.
Several series amalgamate generator pocket infection, CIED-IE and CIED-LI descript duration of therapy and are therefore unhelpful in deciding on the optimum duration of antimicrobials .
Guidelines for management of CIED infections recommend different durations of antibiotic treatment, particularly for CIED-LI, which can result in considerable inappropriate antimicrobial exposure in a vulnerable patient population.
In light of the emergence of bacterial resistance and in order to limit the drug toxicities of antibiotics, it is crucial to offer patients the shortest possible duration of treatment, without losing efficiency.
To this regard, renal failure is one of the most frequent adverse effect during antibiotic treatment, especially in older patients with polymedication and comorbidities, and is responsible indirectly of increasing mortality.
Furthermore, shortening antibiotic therapy would allow to decrease the number of allergy events and Clostridium difficile colitis.
In the most recent European recommendations , if the TEE performed after device removal shows no signs of valve vegetation (i.e. isolated lead vegetation), the follow-up blood cultures are negative, the clinical improvement is good and there are no pulmonary abscesses, treatment duration for 2 weeks post-device extraction can be sufficient but total treatment duration should not be shorter than 4 weeks.
Older U.S guidelines recommend at least 2 weeks of parenteral therapy after extraction of an infected device for patients with bloodstream infection. Patients with sustained (>24 hours) positive blood cultures despite CIED removal and appropriate antimicrobial therapy should receive parenteral therapy for at least 4 weeks, even if TEE is negative for valvular vegetations.
In the British recommendations short course therapy (2 weeks) could be considered if tricuspid valve is structurally normal, no ghost lesions present after system removal on control TEE and rapid clinical response to device removal.
Finally, no clinical trial data are available to define the optimal duration of antimicrobial therapy for CIED-LI and all recommendations are based on retrospective studies and expert opinion. U.S guidelines are mainly based on one retrospective, non-randomized, monocenter cohort study leading to possible confusion and indication bias. However, this study, which is to our knowledge the only one on this topic, 189 patients were included from 1991 to 2003 and presented either a generator pocket infections, a CIED-IE, or a CIED-LI without valvular infection. All results were "pooled" together when describing duration of therapy and are therefore unhelpful in deciding on the optimum duration of antimicrobials. Besides, english recommendations are based on expert opinions, themselves based on case series and pharmacological considerations .
Our hypothesis is therefore that in CIED-LI, 14 days of antimicrobial therapy after device extraction is sufficient regardless of the duration of previous antibiotic therapy if the bacteremia is controlled and if there are (i) no distant infectious foci (abscess), no valvular lesions
Therefore the benefit-risk balance of a shortening of antibiotic therapy for CIED infections needs to be assessed with a high-level of evidence.
This study is endorsed by AEPEI
- Conditions
- Cardiac Devices Infection
- Being tested
- 14-day antibiotic therapy, 28-day antibiotic therapy
- Keywords
- Infections, Antibiotherapy, Implantable extra cardiac devices, Non-inferiority, Randomized
- Medical subject headings
- Infections
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
14-day antibiotic therapyDrug
Also called Experimental arm
The studied intervention will be 14-day antibiotic therapy after removal of infected material
28-day antibiotic therapyDrug
Also called Control arm
The comparator arm will be 28-day antibiotic therapy after removal of infected material
| Study group | Role | What they receive |
|---|---|---|
| Experimental group | Experimental | 14-day antibiotic therapy after removal of infected material Receives: Drug: 14-day antibiotic therapy |
| control group | Active comparator | 28-day antibiotic therapy after removal of infected material Receives: Drug: 28-day antibiotic therapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Mortality,
Mortality linked to infection during or after antibiotic therapy
Measured: at 3 months after randomization,
Rate of relapse of infection
Rate of relapse of infection defined by diagnostic of endocarditis or CIED infection with the same bacteria
Measured: at 3 months after randomization
Rate of relapse of infection
Number of patient whith relapse of infection defined by diagnostic of endocarditis or CIED infection with the same bacteria
Measured: at 6 months after randomization
Rate of a distant infections
Rate of a distant infectious foci with the same bacteria
Measured: at 3 months after randomization
Rate of a distant infectious
Rate of diagnostic of a distant infectious foci with the same bacteria
Measured: 6 months after randomization
Secondary outcomes (10)
Rate of Acute Renal failure,
rate of Acute Renal failure at the end of the antibiotherapy
Measured: at the end of the antibiotherapy period
Rate of Acute Renal failure,
Rate of Acute Renal failure at 3 months after the end of the antibiotherapy antibiotherapy
Measured: at 3 months after the end of the antibiotherapy
Rate of Acute Renal failure,
The Rate of Acute Renal failure at 6 months after the end of the antibiotherapy
Measured: at 6 months after the end of the antibiotherapy
Rate of Clostridium difficile colitis,
The measurements of the event occuring will be taken at 3 months after the end of the antibiotherapy périod
Measured: at 3 months after the end of antibiotherapy
Rate of Clostridium difficile colitis,
The measurements of the event occuring will be taken at 6 months afte rthe end of the antibiotherapy périod
Measured: at 6 months after the end of antibiotherapy
Rate of allergy grade III or IV
The measurements of the event occuring will be taken at 3 months after the end of the antibiotherapy périod
Measured: at 3 months after the end of antibiotherapy
Rate of allergy grade III or IV
The measurements of the event occuring will be taken at 6 months after the end of the antibiotherapy périod
Measured: at 6 months after the end of antibiotherapy
Percentage of unplanned hospitalization
Percentage of unplanned hospitalization within 6 months after the end of antibiotherapy
Measured: within 6 months after the end of antibiotherapy
Percentage of emergency consultation,
Percentage of emergency consultation within 6 months after the end of antibiotherapy
Measured: within 6 months after the end of antibiotherapy
percentage of adverse events related to antibiotherapy
Percentage of adverse events related to antibiotherapy within 6 months after the end of antibiotherapy
Measured: within 6 months after the end of antibiotherapy
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Jan 2024
- Study start30 Jun 2024 (estimated)
- Primary completion30 Jan 2028 (estimated)
- Study completion30 Jun 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cardiac Devices InfectionStudies of the same condition, open and under way.
- More trials run by Assistance Publique - Hôpitaux de ParisThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 500 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06203769
- Sponsor's protocol ID
- APHP220013
- Acronym
- RAID
- Status last verified
- Jan 2024
- First submitted
- 29 Nov 2023
- Last updated
- 12 Jan 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 12 Jan 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Reduction of Antibiotherapy Duration for Infections on Implantable Extra Cardiac Devices Leads: a Randomized Controlled Multicenter Non-inferiority Trial
- ClinicalTrials.gov ID
- NCT06203769
- Acronym / sponsor ID
- RAID / APHP220013
- Conditions
- Cardiac Devices Infection
- Keywords
- Infections, Antibiotherapy, Implantable extra cardiac devices, Non-inferiority, Randomized
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 500 participants (estimated)
- Lead sponsor
- Assistance Publique - Hôpitaux de ParisUniversity, hospital or other
- Study start
- 30 Jun 2024 (estimated)
- Primary completion
- 30 Jan 2028 (estimated)
- Study completion
- 30 Jun 2028 (estimated)
- First posted
- 12 Jan 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The design is an Open-label randomized controlled multicenter non-inferiority trial with blinded assessor which compares 2 antibiotic strategy: 14-day antibiotic therapy after removal of infected material (experimental group) versus 28-day antibiotic therapy after removal of infected material (control group).
Randomization will be centralized, individual 1:1, stratified on center and age (<75 versus >=75 years). Analysis will be reported following CONSORT guidelines for pharmacological trials.
Main analysis will be conducted according to per protocol and intent-to-treat principles. Subgroup analysis will be conducted according to age, classes of antibiotics at baseline and according to resistance testing and baseline renal clearance.
Detailed description
Infections of cardiac implantable electronic devices (CIED) are one of the most frequent complication after implantation of these devices, with an incidence rate estimated at 4.82 / 1000 in Denmark, mainly in the first year post implantation. An american study found that the incidence of CIED infection in the USA increased from 1.53% in 2004 to 2.41% in 2008 and a National Inpatient Sample database study showed an increase from 1.45% to 3.41% (P<0.001) from 2000 through 2012. These figures are constantly increasing and concern mostly older people.
Although the mortality seems to be low compared to those of valvular infection , evaluated at 4% for nonstaphylococcal infection and up to 9% for Staphylococcus aureus related infections, those infections are responsible of numerous morbidities such as iterative hospitalizations, decompensations of other comorbidities and autonomy loss, especially, for older people
Clinical presentations of CIED infections are varied and include generator pocket infections, native or prosthetic CIED-associated valvular endocarditis (CIED-IE) with echocardiographic evidence of valve involvement, and CIED lead infections (CIED-LI) with evidence of lead infection without valve involvement.
In CIED infections, removal of the device is the cornerstone of treatment and is usually required to enable cure in association with antimicrobial therapy for a few weeks. However, although antimicrobial therapy duration after removal of the device are relatively well defined for generator pocket infections (10 - 14 days for the remaining skin and soft tissue infection) and CIED-IE (4 - 6 weeks), the optimal duration of antibiotic treatment in CIED-LI has yet to be determined.
Several series amalgamate generator pocket infection, CIED-IE and CIED-LI descript duration of therapy and are therefore unhelpful in deciding on the optimum duration of antimicrobials.
Guidelines for management of CIED infections recommend different durations of antibiotic treatment, particularly for CIED-LI, which can result in considerable inappropriate antimicrobial exposure in a vulnerable patient population.
In light of the emergence of bacterial resistance and in order to limit the drug toxicities of antibiotics, it is crucial to offer patients the shortest possible duration of treatment, without losing efficiency.
Infections of cardiac implantable electronic devices (CIED) are one of the most frequent complication after implantation of these devices, with an incidence rate estimated at 4.82 / 1000 in Denmark, mainly in the first year post implantation(1). An american study found that the incidence of CIED infection in the USA increased from 1.53% in 2004 to 2.41% in 2008 and a National Inpatient Sample database study showed an increase from 1.45% to 3.41% (P<0.001) from 2000 through 2012. These figures are constantly increasing and concern mostly older people.
Although the mortality seems to be low compared to those of valvular infection , evaluated at 4% for nonstaphylococcal infection and up to 9% for Staphylococcus aureus related infections (4), those infections are responsible of numerous morbidities such as iterative hospitalizations, decompensations of other comorbidities and autonomy loss, especially, for older people
Clinical presentations of CIED infections are varied and include generator pocket infections, native or prosthetic CIED-associated valvular endocarditis (CIED-IE) with echocardiographic evidence of valve involvement, and CIED lead infections (CIED-LI) with evidence of lead infection without valve involvement.
In CIED infections, removal of the device is the cornerstone of treatment and is usually required to enable cure in association with antimicrobial therapy for a few weeks. However, although antimicrobial therapy duration after removal of the device are relatively well defined for generator pocket infections (10 - 14 days for the remaining skin and soft tissue infection) and CIED-IE (4 - 6 weeks) (5), the optimal duration of antibiotic treatment in CIED-LI has yet to be determined.
Several series amalgamate generator pocket infection, CIED-IE and CIED-LI descript duration of therapy and are therefore unhelpful in deciding on the optimum duration of antimicrobials .
Guidelines for management of CIED infections recommend different durations of antibiotic treatment, particularly for CIED-LI, which can result in considerable inappropriate antimicrobial exposure in a vulnerable patient population.
In light of the emergence of bacterial resistance and in order to limit the drug toxicities of antibiotics, it is crucial to offer patients the shortest possible duration of treatment, without losing efficiency.
To this regard, renal failure is one of the most frequent adverse effect during antibiotic treatment, especially in older patients with polymedication and comorbidities, and is responsible indirectly of increasing mortality.
Furthermore, shortening antibiotic therapy would allow to decrease the number of allergy events and Clostridium difficile colitis.
In the most recent European recommendations , if the TEE performed after device removal shows no signs of valve vegetation (i.e. isolated lead vegetation), the follow-up blood cultures are negative, the clinical improvement is good and there are no pulmonary abscesses, treatment duration for 2 weeks post-device extraction can be sufficient but total treatment duration should not be shorter than 4 weeks.
Older U.S guidelines recommend at least 2 weeks of parenteral therapy after extraction of an infected device for patients with bloodstream infection. Patients with sustained (>24 hours) positive blood cultures despite CIED removal and appropriate antimicrobial therapy should receive parenteral therapy for at least 4 weeks, even if TEE is negative for valvular vegetations.
In the British recommendations short course therapy (2 weeks) could be considered if tricuspid valve is structurally normal, no ghost lesions present after system removal on control TEE and rapid clinical response to device removal.
Finally, no clinical trial data are available to define the optimal duration of antimicrobial therapy for CIED-LI and all recommendations are based on retrospective studies and expert opinion. U.S guidelines are mainly based on one retrospective, non-randomized, monocenter cohort study leading to possible confusion and indication bias. However, this study, which is to our knowledge the only one on this topic, 189 patients were included from 1991 to 2003 and presented either a generator pocket infections, a CIED-IE, or a CIED-LI without valvular infection. All results were "pooled" together when describing duration of therapy and are therefore unhelpful in deciding on the optimum duration of antimicrobials. Besides, english recommendations are based on expert opinions, themselves based on case series and pharmacological considerations .
Our hypothesis is therefore that in CIED-LI, 14 days of antimicrobial therapy after device extraction is sufficient regardless of the duration of previous antibiotic therapy if the bacteremia is controlled and if there are (i) no distant infectious foci (abscess), no valvular lesions
Therefore the benefit-risk balance of a shortening of antibiotic therapy for CIED infections needs to be assessed with a high-level of evidence.
This study is endorsed by AEPEI
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Experimental group | Experimental | Drug: 14-day antibiotic therapy14-day antibiotic therapy after removal of infected material |
| control group | Active comparator | Drug: 28-day antibiotic therapy28-day antibiotic therapy after removal of infected material |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Age ≥18 years
- Diagnosis of CIED leads infections, defined by:
- Complete removal of the infected CIED
- Signed informed consent
- French National Health Assurance
Key exclusion criteria (7 listed)
- Current involvement of native or prosthetic heart valve
- Distant infectious foci (such as haematogenous vertebral osteomyelitis, pulmonary abscess…) justifying a prolonged duration of therapy.
- Positive blood culture > 24 hours after cultures despite CIED removal
- CIED infection with Mycobacteria or Fungi
- Women who are pregnant or nursing
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| 14-day antibiotic therapyAlso: Experimental armThe studied intervention will be 14-day antibiotic therapy after removal of infected material | Drug | Experimental group |
| 28-day antibiotic therapyAlso: Control armThe comparator arm will be 28-day antibiotic therapy after removal of infected material | Drug | control group |
Primary outcome
Mortality,
Time frame: at 3 months after randomization,
Mortality linked to infection during or after antibiotic therapy
Rate of relapse of infection
Time frame: at 3 months after randomization
Rate of relapse of infection defined by diagnostic of endocarditis or CIED infection with the same bacteria
Rate of relapse of infection
Time frame: at 6 months after randomization
Number of patient whith relapse of infection defined by diagnostic of endocarditis or CIED infection with the same bacteria
Rate of a distant infections
Time frame: at 3 months after randomization
Rate of a distant infectious foci with the same bacteria
Rate of a distant infectious
Time frame: 6 months after randomization
Rate of diagnostic of a distant infectious foci with the same bacteria
10 secondary outcomes
Rate of Acute Renal failure,
Time frame: at the end of the antibiotherapy period
Rate of Acute Renal failure,
Time frame: at 3 months after the end of the antibiotherapy
Rate of Acute Renal failure,
Time frame: at 6 months after the end of the antibiotherapy
Rate of Clostridium difficile colitis,
Time frame: at 3 months after the end of antibiotherapy
Rate of Clostridium difficile colitis,
Time frame: at 6 months after the end of antibiotherapy
Rate of allergy grade III or IV
Time frame: at 3 months after the end of antibiotherapy
Rate of allergy grade III or IV
Time frame: at 6 months after the end of antibiotherapy
Percentage of unplanned hospitalization
Time frame: within 6 months after the end of antibiotherapy
Percentage of emergency consultation,
Time frame: within 6 months after the end of antibiotherapy
percentage of adverse events related to antibiotherapy
Time frame: within 6 months after the end of antibiotherapy
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Jan 2024.
- Individual participant dataSharing planned: No
Related trials for Cardiac Devices Infection
Active, not recruiting
Barrier-Protect Study
Infection
RecruitingPhase 3
New Treatment of Cardiac Device Infections; Immediate Reimplantation After Removal of Infected System
Endocarditis, Bacterial
Not yet recruitingObservational study
Nucleosome Monitoring Relevance for Outcome Prediction in Critically Ill Patients
Sepsis, Septic Shock
Enrolling by invitationObservational study
Multimodal Physiologic State Intelligence Study
Heart Failure, Cardiomyopathies
RecruitingObservational study
Fatigue Investigation Using Digital Outcomes
Multiple Sclerosis, Long Covid
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing 14-day antibiotic therapy and 28-day antibiotic therapy in people with Cardiac Devices Infection, run by Assistance Publique - Hôpitaux de Paris.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 12 Jan 2024. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Raphael LEPEULE, Infectiologue (01.45.17.80.03 ext. 33, raphael.lepeule@aphp.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Mortality, (time frame: at 3 months after randomization,). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Jan 2024.